Mineralys Therapeutics (NASDAQ: MLYS) insider sales and RSU vesting disclosed

Rhea-AI Filing Summary

Jon Congleton reported Rule 144 transactions in Mineralys Therapeutics common stock, including sales of 16,236 shares on 01/12/2026 for $529,639.51 and 75,000 shares on 03/31/2026 for $1,970,520.69. The filing also shows a vesting of 15,730 restricted share units on 04/10/2026 granted under the issuer's equity compensation plan.

Key Figures

Sale 1 shares: 16,236 shares Sale 1 proceeds: $529,639.51 Sale 2 shares: 75,000 shares +2 more

5 metrics

Sale 1 shares 16,236 shares sale date 01/12/2026

Sale 1 proceeds $529,639.51 proceeds reported for 01/12/2026 sale

Sale 2 shares 75,000 shares sale date 03/31/2026

Sale 2 proceeds $1,970,520.69 proceeds reported for 03/31/2026 sale

RSU vesting 15,730 shares vesting date 04/10/2026 under equity compensation plan

Key Terms

Rule 144, restricted share unit, Merrill Lynch

3 terms

Rule 144 regulatory

"reported Rule 144 transactions in Mineralys Therapeutics common stock"

Rule 144 is a U.S. securities regulation that sets conditions under which restricted or insider-held shares can be legally resold to the public, such as required holding periods, availability of public information, limits on how much can be sold at once, and certain filing requirements. For investors it matters because it determines when previously locked-up shares can enter the market — like a release valve that can increase supply, affect share price, and signal insider intent.

restricted share unit financial

"vesting of 15,730 restricted share units on 04/10/2026"

A restricted share unit (RSU) is a promise by a company to give an employee a set number of company shares at a future date, typically after meeting time or performance conditions. For investors, RSUs matter because when they convert into actual shares they increase the number of shares outstanding (like unlocking more tickets in a game), which can dilute existing holders, and they align employee incentives with company performance, influencing behavior and long-term value.

Merrill Lynch market

"Common Stock | Merrill Lynch 225 Liberty Street Floor 37 New York NY 10281"

Form 144 Filer Information	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 144 NOTICE OF PROPOSED SALE OF SECURITIES PURSUANT TO RULE 144 UNDER THE SECURITIES ACT OF 1933
FORM 144

144: Filer Information

Filer CIK
Filer CCC
Is this a LIVE or TEST Filing?	LIVE TEST
Submission Contact Information
Name
Phone
E-Mail Address

144: Issuer Information

Name of Issuer

SEC File Number

Address of Issuer

Phone

Name of Person for Whose Account the Securities are To Be Sold

See the definition of "person" in paragraph (a) of Rule 144. Information is to be given not only as to the person for whose account the securities are to be sold but also as to all other persons included in that definition. In addition, information shall be given as to sales by all persons whose sales are required by paragraph (e) of Rule 144 to be aggregated with sales for the account of the person filing this notice.

Relationship to Issuer

144: Securities Information

Title of the Class of Securities To Be Sold	Name and Address of the Broker	Number of Shares or Other Units To Be Sold	Aggregate Market Value	Number of Shares or Other Units Outstanding	Approximate Date of Sale	Name the Securities Exchange
Common Stock	Merrill Lynch 225 Liberty Street Floor 37 New York NY 10281	15730	421979.55	82399478	04/13/2026	NASDAQ

Furnish the following information with respect to the acquisition of the securities to be sold and with respect to the payment of all or any part of the purchase price or other consideration therefor:

144: Securities To Be Sold

Title of the Class	Date you Acquired	Nature of Acquisition Transaction	Name of Person from Whom Acquired	Is this a Gift?	Date Donor Acquired	Amount of Securities Acquired	Date of Payment	Nature of Payment *
Common Stock	04/10/2026	Vesting of restricted share unit award	Mineralys Therapeutics, Inc.			15730	04/10/2026	Granted as part of issuer equity compensation plan

* If the securities were purchased and full payment therefor was not made in cash at the time of purchase, explain in the table or in a note thereto the nature of the consideration given. If the consideration consisted of any note or other obligation, or if payment was made in installments describe the arrangement and state when the note or other obligation was discharged in full or the last installment paid.

Furnish the following information as to all securities of the issuer sold during the past 3 months by the person for whose account the securities are to be sold.

144: Securities Sold During The Past 3 Months

Name and Address of Seller	Title of Securities Sold	Date of Sale	Amount of Securities Sold	Gross Proceeds
Jon Congleton 150 N. RADNOR CHESTER RD. SUITE F200 RADNOR PA 19087	Common Stock	01/12/2026	16236	529639.51
Jon Congleton 150 N. RADNOR CHESTER RD SUITE F200 RADNOR PA 19087	Common Stock	03/31/2026	75000	1970520.69

144: Remarks and Signature

Remarks

Date of Notice

Date of Plan Adoption or Giving of Instruction, If Relying on Rule 10b5-1

ATTENTION:

The person for whose account the securities to which this notice relates are to be sold hereby represents by signing this notice that he does not know any material adverse information in regard to the current and prospective operations of the Issuer of the securities to be sold which has not been publicly disclosed. If such person has adopted a written trading plan or given trading instructions to satisfy Rule 10b5-1 under the Exchange Act, by signing the form and indicating the date that the plan was adopted or the instruction given, that person makes such representation as of the plan adoption or instruction date.

Signature

ATTENTION: Intentional misstatements or omission of facts constitute Federal Criminal Violations (See 18 U.S.C. 1001)

FAQ

Who sold Mineralys Therapeutics (MLYS) shares?

The filing shows Jon Congleton as the reporting person. It lists sales of 16,236 shares on 01/12/2026 and 75,000 shares on 03/31/2026 under Rule 144.

How many shares were sold and for what values in the MLYS Form 144?

The Form 144 lists two transactions: 16,236 shares sold for $529,639.51 and 75,000 shares sold for $1,970,520.69, with respective trade dates of 01/12/2026 and 03/31/2026.

Did Mineralys report any equity grants or vesting in this filing (MLYS)?

Yes. The filing records the vesting of 15,730 restricted share units on 04/10/2026, granted as part of the issuer's equity compensation plan.

Which broker or dealer is named in the securities information for MLYS?

The securities line references Merrill Lynch at 225 Liberty Street, Floor 37, New York, NY. No further broker role details are provided in the excerpt.